Orthocell Share Price Up 11.4% With Clinical Trial Update

By ,

Shares of regenerative medicine company Orthocell Ltd [ASX:OCC] have soared in today’s trading, currently up over 11% at time of writing.

Orthocell focuses on regenerating mobility for patients through products that can facilitate tendon and soft tissue repair.

One such product developed by the company is CelGro — a sort of next-gen collagen scaffold that is ‘bio-compatible, bio-absorbable and mechanically strong…mak[ing] it ideal for use as a tissue reconstruction and repair device’.

The biotech small-cap released the final results today of their CelGro clinical trial, which was successfully completed back in May.

We covered this initial announcement here at Money Morning, noting that the future results of the trial — if positive — could provide a boon for the company.

And it looks like it has.

A breakthrough in tendon regeneration

The final results report notes that 89% of patients participating in the clinical trial were able to return back to work after their CelGro tendon regeneration surgery with pain-free function.

It was also noted that no patients needed follow-up re-tear surgery, even two years post-CelGro surgery.

One patient was so impressed with the results that he has now ‘gone back to get [his] other shoulder done’.

These findings round out CelGro’s trials, with positive data announced in nerve, tendon and bone applications.

Orthocell Managing Director Paul Anderson notes that the results show that ‘CelGro is proving to be a breakthrough soft tissue reconstruction platform technology’.

A breakthrough in a billion dollar industry

As per this latest announcement, Orthocell claims to have a ‘clear commercialisation strategy’ for their CelGro product.

Its recent European regulatory approval means the product can now be marketed and sold within the EU, and this process is being ready to also be done in the US.

Combining nerve, tendon and bone regeneration, CelGro has an addressable market of approximately US$2.7 billion.

In rotator cuff tendon repair alone, the addressable market is worth around US$1 billion, with nearly $500,000 procedures per annum that could use CelGro.

And Orthocell believe this market could expand even further, once surgeons develop a preference for Orthocell products, which can ‘achieve better results in the shortest possible time for their patients’.

Hopefully this clinical preference will be reflected in the company’s share price.

Regardless, a 46.67% year-on-year return is commendable, particularly for a developing small-cap biotech.

But that’s the beauty of the biotech sector…it’s a mixture of fizzers and winners, and it can be hard to pick the latter.

Luckily for you, we have a free report on how to invest in biotech stocks to help get you started. Download now.

Regards,

Ryan Clarkson-Ledward

For Money Morning

About Ryan Clarkson-Ledward

Ryan Clarkson-Ledward is an Editor at Money Morning.

Ryan holds degrees in both communication and international business. He helps bring Money Morning readers the latest market updates, both locally and abroad. Ryan tackles all the issues investors need to know about that the mainstream media neglects.

Ryan is also the Editor…

Orthocell Share Price Up 25% on FDA Approval (ASX:OCC)

Drug development is a long and tedious process, often taking years to reach commercialisation. Small-cap biotech company Orthocell Ltd [ASX:OCC] knows this all too well, having spent years bringing their tissue repair…

Orthocell Pauses Trading in Hopes for More Cash (ASX:OCC)

Small-cap biotech company Orthocell Ltd [ASX:OCC] has entered a trading halt today. A request that will give them time to announce a fresh capital raise. As it stands we are scant for details.

Orthocell Share Price Up 21.5% with More CelGro Results (ASX: OCC)

Aussie biotech Orthocell Ltd [ASX:OCC] has seen a magnificent spike in their share price today, up a whopping 21.5% at time of writing. Results from clinical trials of their core regenerative medical solution CelGro, have led to such spikes in the Orthocell share price throughout 2019, and today is no exception…

Best Performing Stocks on the ASX for May

The ASX 200 recorded a 1% rise over the last month, the big winner being Lynas Corporation Ltd [ASX:LYC] with a 54% gain. Today we will be looking at what has been driving the best performing stocks on the ASX for May.

A Look at the Orthocell Share Price: Can It Keep Going Up? 

Despite a recent pullback, it has been an exciting ride for investors with the Orthocell share price going through the roof on 8 May .Today we will be looking at what caused Orthocell’s remarkable rise and its prospects going forward.